http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004062620-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b94ac7ee4304aee131c1ed30f4e718b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80c0f5a1693101170ee60e4c75cb6f40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59
filingDate 2004-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af65eac385bb5a69ce24bd9086c16112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de79457fae7b9e589a08c0fdba91172
publicationDate 2004-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004062620-A3
titleOfInvention Paricalcitol as a chemotherapeutic agent
abstract The invention provides methods of reducing the severity of a proliferative disorder. One method involves administering to an individual having the proliferative disorder an effective amount of paricalcitol, wherein the paricalcitol reduces cellular proliferation, with the proviso that the cancer is not prostate cancer or head and neck squamous cell carcinoma. Another method of reducing the severity of a proliferative disorder provided by the invention involves administering to an individual having the proliferative disorder an effective amount of paricalcitol and an anti- cancer agent, wherein the combination of paricalcitol and the anti-cancer agent reduces cell proliferation, with the proviso that the proliferative disorder is not prostate cancer or head and neck squamous cell carcinoma.
priorityDate 2003-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6624138-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426067595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395789
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281104

Total number of triples: 24.